Latest on Anabolic Agents for Osteoporosis Treatment

被引：2
|
作者：
di Filippo, Luigi [1 ,2 ]
Rosen, Clifford J. [3 ]
机构：
[1] Univ Vita Salute San Raffaele, Inst Endocrine & Metab Sci, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Main Ehlth Inst Res, Ctr Clin & Translat Res, Scarborough, ME 04074 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2024年 / 53卷 / 04期
关键词：
Osteoporosis; Anabolics; Teriparatide; Abaloparatide; Romosozumab; Blosozumab; Fragility fractures; Glucocorticoids; PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ABALOPARATIDE; TERIPARATIDE; ROMOSOZUMAB; FRACTURE; RISK; PLACEBO;
D O I：
10.1016/j.ecl.2024.08.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use is currently investigated also in fracture healings setting.
引用
收藏
页码：513 / 523
页数：11
相关论文
共 50 条
12345